

DR. HERWIG P. MOLL

Nationality: Austria

DOB: 16.11.1976

Medical University of Vienna

Center for Physiology and Pharmacology

Waehringer Str. 13a, 1080 Vienna, Austria

Email: herwig.moll@meduniwien.ac.at

phone: (+43) (+43) 1 40160 71230

1. OVERVIEW

RESEARCH INTERESTS

Tumor biology/angiogenesis, vascular biology and cardiovascular disease, animal models of disease, inflammation, JAK/STAT signaling

EDUCATION AND TRAINING AT A GLANCE

Institution and Location	Dates Attended	Degree (if applicable)	Conferred (mm/yyyy)	Field of Study
Medical University of Vienna, Center for Physiology and Pharmacology, Austria	11/2014- to date			<i>Tumor Biology</i> <i>Vascular Biology</i>
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA	04/2011- 09/2014			<i>Vascular Biology</i>
Medical University of Vienna, Department of Surgery, Austria	06/2010- 09/2010			<i>Vascular Biology</i> <i>Tumor Biology</i>
University of Natural Resources and Applied Life Sciences, Vienna, Austria	2007- 2010	Doctor naturalium technicarum	06/2010	<i>Doctorate in Agricultural Sciences - Biotechnology</i>
Universitat de Barcelona, Facultat de Farmàcia, Barcelona, Spain	2001- 2002			<i>Food Technology</i>
University of Natural Resources and Applied Life Sciences, Vienna, Austria	1996- 2006	Diplom- Ingenieur	09/2006	<i>Food Science and Biotechnology</i>
Bundesrealgymnasium Stockerau	1988- 1995		1.6.1995	

2. RESEARCH POSITIONS/EMPLOYMENT

11/2014 – to date	Assistant Medical University of Vienna Center for Physiology and Pharmacology
04/2011 – 09/2014	Postdoctoral Research Fellow Beth Israel Deaconess Medical Center and Harvard Medical School Department of Surgery, Boston, Massachusetts, United States Principal Investigator: Christiane Ferran, MD, PhD
10/2010 – 02/2011	Research Associate Jungbunzlauer AG Austria, Department of Product Development Pernhofen, Austria

- 09/2007 – 05/2010 PhD-student
 Medical University of Vienna, Austria
 Department of Surgery
 PhD Thesis: *“Induction of Interferon Regulated Genes in Endothelial Cells: Differential Regulation by Interferon Subtypes and Pro-Inflammatory Cytokines”*, Principal Investigator: Christine Brostjan, PhD
- 01/2007 – 08/2007 PhD-student
 Medical University of Vienna, Austria
 Department of Vascular Biology and Thrombosis Research
“Identification and characterization of atheroprotective genes in porcine vasculature, potentially counteracting xenograft rejection”, Principal Investigator: Rainer deMartin, PhD
- 06/2005-12/2006 Diploma student
 Medical University of Vienna, Austria
 Department of Surgery
 Diploma Thesis: *“Induction of Interferon Regulated Genes in Endothelial Cells: Characterization of a Tumor Derived Stimulus and Endothelial Receptor Interactions”*, Principal Investigator: Christine Brostjan, PhD

3. RESEARCH GRANTS

- 2020 – 2024 Austrian Science Fund (FWF-P32900; Co-Applicant with Emilio Casanova (€ 100k)
 2019 – 2020 Fellingner Cancer Foundation (€ 25k)
 2018 – 2019 CCC Research Grant (€ 50k)
 2015 - 2017 Fellingner Cancer Foundation (€ 25k)
 2012 - 2014 Erwin Schroedinger Fellowship (FWF-J3398-B23) (€ 140k)

4. INTERNATIONAL LECTURES:

- 10/2018 *Breaking bad family ties: Pan-ERBB blockers inhibit KRAS driven lung tumorigenesis* (University of Ulm, Germany, invited N27 talk, Host: Dr. Jan Tuckermann)
- 09/2018 Lung tumors escape immune surveillance by downregulation of A20 (EMBO: Cellular signaling and Cancer Therapy, Cavtat, Croatia)
- 09/2017 *Partial Loss of A20 exacerbates IFN γ dependent Transplant Arteriosclerosis through De-Regulation of IFN β* . (Joint Meeting of the Federation of European Physiological Societies, Vienna, Austria)
- 07/2014 *Partial Loss of A20 Aggravates Transplant Arteriosclerosis through De-Regulation of IFN β /STAT1 Axis, Thereby Enhancing Pathologic IFN γ signaling*. (World Transplant Congress, San Francisco, United States)

5. AWARDS, MEMBERSHIPS, PROFESSIONAL ACTIVITIES

AWARDS

- 04/2018 Poster Prize CCC-TRIO – Translational Research & Immuno-Oncology (€ 2.5k)
 05/2014 Excellence in Surgery Research – Harvard Medical School Research Day
 07/2012 Poster Prize – Center for Vascular Biology Research 8th Annual Research Retreat
 06/2012 Poster of Distinction – American Transplant Congress 2012
 05/2012 Excellence in Surgery Research – Inaugural Harvard Medical School Surgery Research Day 2012
 11/2011 Beth Israel Deaconess Medical Center Surgery Research Symposium Award 2011 (Harvard Medical School)

MEMBERSHIPS

- 2018-to date European Association for Cancer Research
 2013-to date European Atherosclerosis Society
 2012-to date American Heart Association

EXPERT OPINION

Reviewer for Cancer Medicine, Cancers, Cytokine, Oxidative Medicine and Cellular Longevity, Pulmonary Pharmacology & Therapeutics, Biomedicine & Pharmacotherapy, etc.

6. 10 MOST RELEVANT PUBLICATIONS

1. Bousquet Mur, E., Bernardo, S., Papon, L., Mancini, M., Fabbrizio, E., Goussard, M., Ferrer, I., Giry, A., Quantin, X., Pujol, J.L., Calvayrac, O., **Moll, H.P.**, Glasson, Y., Piro, N., Turtoi, A., Canamero, M., Wong, K.K., Yarden, Y., Casanova, E., Soria, J.C., Colinge, J., Siebel, C.W., Mazieres, J., Favre, G., Paz-Ares, L. & Maraver, A. *Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma.* J Clin Invest 130, 612-624 (2020).
2. Sdelci, S., Rendeiro, A.F., Rathert, P., You, W., Lin, J.G., Ringler, A., Hofstätter, G., **Moll, H.P.**, Gurtl, B., Farlik, M., Schick, S., Klepsch, F., Oldach, M., Buphamalai, P., Schischlik, F., Majek, P., Parapatics, K., Schmidl, C., Schuster, M., Penz, T., Buckley, D.L., Hudecz, O., Imre, R., Wang, S.Y., Maric, H.M., Kralovics, R., Bennett, K.L., Muller, A.C., Mechtler, K., Menche, J., Bradner, J.E., Winter, G.E., Klavins, K., Casanova, E., Bock, C., Zuber, J. & Kubicek, S. *MTHFD1 interaction with BRD4 links folate metabolism to transcriptional regulation.* Nat Genet 51, 990-998 (2019).
3. **Moll, H.P.**, Mohrherr, J., Blaas, L., Musteanu, M., Stiedl, P., Grabner, B., Zboray, K., König, M., Stoiber, D., Rulicke, T., Strehl, S., Eferl, R. & Casanova, E. A Mouse Model to Assess STAT3 and STAT5A/B Combined Inhibition in Health and Disease Conditions. Cancers 11(2019).
4. Mohrherr, J., Haber, M., Breitenecker, K., Aigner, P., Moritsch, S., Voronin, V., Eferl, R., Moriggl, R., Stoiber, D., Gyorffy, B., Brcic, L., Laszlo, V., Dome, B., Moldvay, J., Dezso, K., Bilban, M., Popper, H., **Moll, H.P.** & Casanova, E. *JAK-STAT inhibition impairs K-RAS-driven lung adenocarcinoma progression.* Int J Cancer 145, 3376-3388 (2019).
5. Aigner, P., Mizutani, T., Horvath, J., Eder, T., Heber, S., Lind, K., Just, V., **Moll, H.P.**, Yeroslaviz, A., Fischer, M.J.M., Kenner, L., Gyorffy, B., Sill, H., Grebien, F., Moriggl, R., Casanova, E. & Stoiber, D. *STAT3beta is a tumor suppressor in acute myeloid leukemia.* Blood Adv 3, 1989-2002 (2019).
6. Zboray, K., Mohrherr, J., Stiedl, P., Pranz, K., Wandruszka, L., Grabner, B., Eferl, R., Moriggl, R., Stoiber, D., Sakamoto, K., Wagner, K.U., Popper, H., Casanova, E. & **Moll, H.P.** AKT3 drives adenoid cystic carcinoma development in salivary glands. Cancer Med 7, 445-453 (2018).
7. **Moll, H.P.**, Pranz, K., Musteanu, M., Grabner, B., Hruschka, N., Mohrherr, J., Aigner, P., Stiedl, P., Brcic, L., Laszlo, V., Schramek, D., Moriggl, R., Eferl, R., Moldvay, J., Dezso, K., Lopez-Casas, P.P., Stoiber, D., Hidalgo, M., Penninger, J., Sibilica, M., Gyorffy, B., Barbacid, M., Dome, B., Popper, H. & Casanova, E. *Afatinib restrains K-RAS-driven lung tumorigenesis.* Sci Transl Med 10(2018).
8. **Moll, H.P.**, Lee, A., Peterson, C.R., Revuelta Cervantes, J., Wojcik, B.M., Parulkar, A., Mele, A., LoGerfo, P.J., Siracuse, J.J., Csizmadia, E., da Silva, C.G. & Ferran, C. *A20 Haploinsufficiency Aggravates Transplant Arteriosclerosis in Mouse Vascular Allografts: Implications for Clinical Transplantation.* Transplantation 100, e106-e116 (2016).
9. Grabner, B., Schramek, D., Mueller, K.M., **Moll, H.P.**, Svinka, J., Hoffmann, T., Bauer, E., Blaas, L., Hruschka, N., Zboray, K., Stiedl, P., Nivarthi, H., Bogner, E., Gruber, W., Mohr, T., Zwick, R.H., Kenner, L., Poli, V., Aberger, F., Stoiber, D., Egger, G., Esterbauer, H., Zuber, J., Moriggl, R., Eferl, R., Gyorffy, B., Penninger, J.M., Popper, H. & Casanova, E. *Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis.* Nat Commun 6, 6285 (2015).
10. **Moll, H.P.**, Lee, A., Minussi, D.C., da Silva, C.G., Csizmadia, E., Bhasin, M. & Ferran, C. *A20 regulates atherogenic interferon (IFN)-gamma signaling in vascular cells by modulating basal IFNbeta levels.* J Biol Chem 289, 30912-30924 (2014).